Figure 2.
Longitudinal PET/CT imaging in SK-OV-3 xenograft bearing mice. (A) Representative coronal (top) and axial (bottom) images 70 hours post-injection of random, β-Gal, endoS2 and endoS2-R modified 89Zr-DFO-trastuzumab. Arrows designate the tumors. (B) Image-derived biodistribution of 89Zr-DFO-trastuzumab in major organs over the imaging time-course (N=4/tracer). (C) Mean and (D) maximum tumor uptakes at 24, 70 and 120 hours post-injection of tracers (N=4/tracer).